Braden Parker
Corporate Officer/Principal chez ORCHARD THERAPEUTICS PLC
Postes actifs de Braden Parker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - | - |
Historique de carrière de Braden Parker
Anciens postes connus de Braden Parker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Formation de Braden Parker
| The Leonard N Stern School of Business | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Braden Parker
- Expérience